Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,369
Recruiting: 3,967
Ph III recruiting: 537
Growth YoY: +9.4%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,405)

clinicaltrialsPublishedShowing 751–800 of 8,903 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07777848	A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC).	not yet recruiting	Phase 2	114	Ractigen Therapeutics.OTHER	1	Sep 15, 2026	clinicaltrials
NCT07783321	A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)	not yet recruiting	Phase 3	404	Sichuan Baili Pharmaceutical Co., Ltd.